ECSP10010295A - Formulacion de anticuerpo - Google Patents

Formulacion de anticuerpo

Info

Publication number
ECSP10010295A
ECSP10010295A EC2010010295A ECSP10010295A ECSP10010295A EC SP10010295 A ECSP10010295 A EC SP10010295A EC 2010010295 A EC2010010295 A EC 2010010295A EC SP10010295 A ECSP10010295 A EC SP10010295A EC SP10010295 A ECSP10010295 A EC SP10010295A
Authority
EC
Ecuador
Prior art keywords
antibody
formulation
preparation
relates
present
Prior art date
Application number
EC2010010295A
Other languages
English (en)
Inventor
Hanns-Christian Mahler
Christine Wurth
Michael Adler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40532665&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP10010295A publication Critical patent/ECSP10010295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a una formulación de anticuerpo anti-CD20 humano, a un proceso para su preparación y a usos de la misma.
EC2010010295A 2007-12-21 2010-06-21 Formulacion de anticuerpo ECSP10010295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07150335 2007-12-21

Publications (1)

Publication Number Publication Date
ECSP10010295A true ECSP10010295A (es) 2010-07-30

Family

ID=40532665

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010295A ECSP10010295A (es) 2007-12-21 2010-06-21 Formulacion de anticuerpo

Country Status (33)

Country Link
US (2) US20090162352A1 (es)
EP (1) EP2234600B1 (es)
JP (1) JP5881950B2 (es)
KR (1) KR101247418B1 (es)
CN (2) CN101896163A (es)
AR (1) AR069788A1 (es)
AU (1) AU2008340429C1 (es)
BR (1) BRPI0820819B1 (es)
CA (1) CA2708869C (es)
CL (1) CL2008003788A1 (es)
CO (1) CO6280464A2 (es)
CR (1) CR11461A (es)
CY (1) CY1115932T1 (es)
DK (1) DK2234600T3 (es)
EC (1) ECSP10010295A (es)
ES (1) ES2511844T3 (es)
HK (1) HK1214947A1 (es)
HR (1) HRP20141249T1 (es)
IL (1) IL206103A (es)
MA (1) MA31984B1 (es)
MX (1) MX2010006395A (es)
MY (1) MY171841A (es)
NZ (1) NZ585516A (es)
PE (1) PE20091328A1 (es)
PL (1) PL2234600T3 (es)
PT (1) PT2234600E (es)
RS (1) RS53551B1 (es)
RU (1) RU2476238C2 (es)
SI (1) SI2234600T1 (es)
TW (1) TWI404728B (es)
UA (1) UA101487C2 (es)
WO (1) WO2009080541A1 (es)
ZA (1) ZA201003907B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60324700D1 (de) * 2002-10-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
ME03330B (me) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
EP1710255A4 (en) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
TW200722518A (en) * 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
AU2006256041B2 (en) * 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20090028854A1 (en) * 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
JPWO2008007755A1 (ja) * 2006-07-13 2009-12-10 中外製薬株式会社 細胞死誘導剤
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2013266987B2 (en) * 2009-09-11 2016-11-10 F. Hoffmann-La Roche Ag Highly concentrated pharmaceutical formulations comprising anti - CD20 antibody
KR20120110175A (ko) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 항체 제제
MY174760A (en) 2010-03-01 2020-05-13 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
SG11201401360XA (en) 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
ES2749457T3 (es) 2012-01-27 2020-03-20 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
CN103059258A (zh) * 2012-12-07 2013-04-24 青岛文创科技有限公司 一种有机硅改性水性聚氨酯乳液
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103012731A (zh) * 2012-12-17 2013-04-03 青岛森淼实业有限公司 一种水性聚氨酯抗起球剂的制备方法
NZ711567A (en) * 2013-03-13 2020-04-24 Genentech Inc Antibody formulations
WO2014140361A1 (en) * 2013-03-15 2014-09-18 Takeda Gmbh Formulation of an antibody and use thereof
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US20160137727A1 (en) 2014-09-15 2016-05-19 Genentech, Inc. Antibody formulations
CN105708811A (zh) * 2014-12-01 2016-06-29 西藏海思科药业集团股份有限公司 一种稳定的重组人抗cd20单克隆抗体的冻干制剂
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2018096445A1 (en) * 2016-11-22 2018-05-31 Biocon Limited Stable formulation of recombinant humanized monoclonal antibody
CN108261391B (zh) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR20200067196A (ko) * 2017-10-19 2020-06-11 에프. 호프만-라 로슈 아게 올비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
BR112020020703A2 (pt) * 2018-04-10 2021-01-12 Dr. Reddy's Laboratories Limited Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 .
WO2020055360A2 (en) * 2018-08-10 2020-03-19 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The parenteral composition comprising carfilzomib
EP3890778A4 (en) * 2018-12-03 2022-08-03 Agensys, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME
CN114555117A (zh) * 2019-10-12 2022-05-27 百奥泰生物制药股份有限公司 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
CN113081955B (zh) * 2020-01-09 2023-10-24 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的制剂
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN113855798A (zh) * 2021-09-30 2021-12-31 佛山汉腾生物科技有限公司 抗cd20的抗体制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CA2292730C (en) * 1997-06-13 2008-09-16 Genentech, Inc. Stabilized antibody formulation
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP2005506340A (ja) * 2001-10-16 2005-03-03 シムバイオンティクス インコーポレイテッド 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物
BRPI0411276A (pt) * 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
ME03330B (me) * 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR057233A1 (es) * 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP1998806A1 (en) * 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Anti-igf-1r human monoclonal antibody formulation

Also Published As

Publication number Publication date
HK1214947A1 (zh) 2016-08-12
US20150353640A1 (en) 2015-12-10
PL2234600T3 (pl) 2015-02-27
NZ585516A (en) 2012-07-27
ZA201003907B (en) 2011-03-30
JP2011506538A (ja) 2011-03-03
ES2511844T3 (es) 2014-10-23
WO2009080541A1 (en) 2009-07-02
CN101896163A (zh) 2010-11-24
AU2008340429A1 (en) 2009-07-02
KR101247418B1 (ko) 2013-03-25
US20090162352A1 (en) 2009-06-25
RS53551B1 (en) 2015-02-27
CL2008003788A1 (es) 2010-02-19
BRPI0820819B1 (pt) 2021-06-08
UA101487C2 (en) 2013-04-10
KR20100087038A (ko) 2010-08-02
EP2234600B1 (en) 2014-08-20
CO6280464A2 (es) 2011-05-20
CN105126099A (zh) 2015-12-09
PE20091328A1 (es) 2009-09-03
PT2234600E (pt) 2014-09-25
RU2476238C2 (ru) 2013-02-27
AU2008340429C1 (en) 2016-09-08
CA2708869C (en) 2016-06-28
CA2708869A1 (en) 2009-07-02
MA31984B1 (fr) 2011-01-03
IL206103A0 (en) 2010-11-30
HRP20141249T1 (en) 2015-03-13
SI2234600T1 (sl) 2014-12-31
AU2008340429B2 (en) 2015-02-12
BRPI0820819A2 (pt) 2015-06-16
DK2234600T3 (da) 2014-09-08
AR069788A1 (es) 2010-02-17
JP5881950B2 (ja) 2016-03-09
CR11461A (es) 2010-08-16
EP2234600A1 (en) 2010-10-06
TWI404728B (zh) 2013-08-11
TW200934792A (en) 2009-08-16
MX2010006395A (es) 2010-07-01
CY1115932T1 (el) 2017-01-25
IL206103A (en) 2016-07-31
RU2010129481A (ru) 2012-01-27
MY171841A (en) 2019-11-04

Similar Documents

Publication Publication Date Title
ECSP10010295A (es) Formulacion de anticuerpo
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
TR200900882A2 (tr) Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
BRPI0800596A2 (pt) método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
AR089079A1 (es) Formulacion de anticuerpo anti-cd44
WO2009098019A3 (de) Hauptpflegezubereitung zur pflege von gestresster haut